Molecular Testing and Genomic Landscape of Non-Small Cell Lung Cancer in Malaysia: Real-World Evidence From a Resource-Limited Setting.
Researchers
Seng Wee Cheo, Shirin Hui Tan, Ai Rene Ong, Jenny Kha Mieng Chong, Elsie Sie Hui Pui, Yi Leen Chan, Suan Yin Lim, Nur Qistina Nabihah Ahmad Zaki, Geok Gee Yeo, Choon Seong Ang, Qin Jian Low, Chan Sin Chai, Sze Shyang Kho, Siew Teck Tie, Adam Malik Ismail, Weang Kee Ho, Pei Jye Voon
Abstract
Molecular profiling is essential for the management of non-small cell lung cancer (NSCLC), yet access to comprehensive testing remains inequitable in low- and middle-income settings. We evaluated real-world molecular testing patterns and the genomic landscape of NSCLC in Sarawak, Malaysia, to identify gaps in precision oncology implementation. We retrospectively analyzed patients diagnosed with NSCLC between January 2017 and December 2023 at a tertiary center. Demographic, clinicopathologic, and molecular testing data were analyzed using descriptive and multivariable analyses. Among 577 NSCLC cases, 76.6% presented with advanced disease. The cohort was enriched with substantial representation of indigenous populations (Iban 23.4%, Bidayuh 10.9%). Molecular testing was performed in 86.7% overall and 91.2% of stage IV cases. However, most testing relied on single-gene assays (81.6%), whereas only 8.5% underwent next-generation sequencing (NGS), revealing a diagnostic paradox of high testing uptake but limited genomic depth. PD-L1 testing was performed in 19.2% of patients. Epidermal growth factor receptor (<i>EGFR</i>) mutations were the most common alteration (52.9%), followed by anaplastic lymphoma kinase (<i>ALK</i>) fusions (6.3%). Never-smoking status (odds ratio [OR], 8.68, <i>P</i> < .001) and age ≥70 years (OR, 1.91, <i>P</i> = .043) were independently associated with <i>EGFR</i> mutations. Exploratory multivariable analysis suggested higher odds of <i>ALK</i> positivity among patients of Bidayuh and other ethnicity although this estimate was imprecise because of the small number of <i>ALK</i>-positive cases. High testing rates alone are insufficient to deliver precision oncology. Reliance on limited assays risks underdetection of actionable genomic alterations and perpetuates inequities in access to targeted therapies and clinical trials. Expanding equitable access to comprehensive genomic profiling and integrating it into routine cancer care are essential for closing this implementation gap and advancing precision oncology in under-represented populations.Source: PubMed (PMID: 43050624)View Original on PubMed